The CTC counts and genetic mutations carried by CTCs were then assessed in cancer patients who were confirmed to have the mutations based on tissue testing, including five EGFR 19del mutation-positive NSCLC samples, five KRAS G12D mutation-positive pancreatic adenocarcinoma patients, and five BRAF V600E mutation-positive CRC patients (Tables S6). This evidence concerns the gene KRAS and colorectal carcinoma.